Laboratory Safety of Dupilumab in Patients Aged 6–11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial

Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial

(2021) Elaine C. Siegfried et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial

(2020) Amy S. Paller et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children

(2020) A. Wollenberg et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult, longstanding disease

(2019) Patrick M. Brunner et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Dupilumab shows long-term safety and efficacy in moderate-to-severe atopic dermatitis patients enrolled in a phase 3 open-label extension study

(2019) Mette Deleuran et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Update on eosinophilic granulomatosis with polyangiitis

(2019) Shunsuke Furuta et al.   ALLERGOLOGY INTERNATIONAL

Laboratory safety of dupilumab in moderate‐to‐severe atopic dermatitis: results from three phase III trials ( LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS )

(2019) A. Wollenberg et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

(2019) Claus Bachert et al.   LANCET

Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase II a open‐label trial and subsequent phase III open‐label extension

(2019) M.J. Cork et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis

(2019) Eric L. Simpson et al.   JAMA Dermatology

Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation

(2019) Audrey Le Floc’h et al.   ALLERGY

Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape

(2018) Mark Boguniewicz et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement

(2018) A.M. Drucker et al.   BRITISH JOURNAL OF DERMATOLOGY

Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t

(2018) M. de Bruin-Weller et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma

(2018) Klaus F. Rabe et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

(2018) Mario Castro et al.   NEW ENGLAND JOURNAL OF MEDICINE

The fear of needles: A systematic review and meta-analysis

(2018) Jennifer McLenon et al.   JOURNAL OF ADVANCED NURSING

Commonality of the IL-4/IL-13 pathway in atopic diseases

(2017) Namita A. Gandhi et al.   Expert Review of Clinical Immunology

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

(2017) Andrew Blauvelt et al.   LANCET

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

(2016) Eric L. Simpson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management

(2015) Matthieu Groh et al.   European Journal of Internal Medicine

Important roles of platelets as immune cells in the skin

(2015) Risa Tamagawa-Mineoka   JOURNAL OF DERMATOLOGICAL SCIENCE

Targeting key proximal drivers of type 2 inflammation in disease

(2015) Namita A. Gandhi et al.   NATURE REVIEWS DRUG DISCOVERY

Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes

(2014) L. E. Macdonald et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice

(2014) A. J. Murphy et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis

(2012) Julia K. Gittler et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Elevated Platelet Activation in Patients with Atopic Dermatitis and Psoriasis: Increased Plasma Levels of β-Thromboglobulin and Platelet Factor 4

(2008) Risa Tamagawa-Mineoka et al.   ALLERGOLOGY INTERNATIONAL